Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.
Nanobiotix’s NBTXR3, a compound designed to increase the efficiency of radiotherapy, also has the ability to make a tumor responsive to immunotherapy, the company reported. A lot of research ... Read more
Updated clinical trial data of Immune Design’s two lead immunotherapy candidates indicate the treatments hold promise to become new additions to the portfolio of immune-targeting compounds available to oncologists. ... Read more
Dr. Jim Allison, an immuno-oncology pioneer at the University of Texas MD Anderson Cancer Center in Houston, has been named to TIME magazine’s list of the world’s 100 most influential people. ... Read more
Opdivo (nivolumab) likely will not be available for United Kingdom patients with head and neck cancers, because the U.K. cost-benefit agency, the National Institute for Health and Care Excellence ... Read more
Using an advanced computational analysis may help scientists predict which patients are likely to respond to immunotherapy. But researchers — who hope a more integrated picture of the immune response might ... Read more
New insights into the molecular processes leading to the exhaustion of tumor-fighting T-cells may allow researchers to develop new methods of boosting cancer immunotherapy approaches. In a recent study ... Read more